By Stefan Zoricic, MSc
Founder & CEO, MedFriend Ltd

At PCMG, one of the most thought-provoking discussions focused on the acceleration of clinical development in Asia, with particular attention to China’s rapid evolution as a serious force in global pharmaceutical research and innovation.

The explanation presented was compelling. China’s transformation did not happen by accident. It was the result of deliberate regulatory, financial, and strategic reforms that reshaped the country’s clinical development environment.

China began reforming its drug review and approval system in 2015, aiming to address long-standing bottlenecks in regulatory review and improve the quality and credibility of clinical trial data. In 2017, China’s drug regulatory authority formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, better known as ICH, marking a significant step towards alignment with international regulatory standards. By 2018, the National Medical Products Administration had also been elected to the ICH Management Committee, further reinforcing China’s integration into the global regulatory framework.

That same period also saw important changes in access to capital. In 2018, Hong Kong introduced Chapter 18A of its listing rules, enabling qualifying pre-revenue biotech companies to list publicly. This was a major shift. It gave early-stage biotech companies, many of which would traditionally have struggled to access public markets before profitability, a clearer route to funding and growth.

Taken together, these reforms helped move China from being perceived primarily as a market for global pharmaceutical companies into a country increasingly capable of originating, developing, funding, and commercialising innovation.

However, one element of the discussion deserves more attention: the role of COVID-19.

COVID did not create China’s biotech and clinical development ecosystem. The foundations were already being laid through regulatory reform, ICH alignment, investment in infrastructure, and capital market modernisation. But it is difficult to ignore the extent to which the pandemic acted as an accelerant.

COVID changed the way governments, regulators, healthcare systems, investors, and the public understood pharmaceutical development. Speed was no longer simply a commercial advantage. It became a matter of public health resilience, national preparedness, and strategic sovereignty.

Before the pandemic, faster clinical development was often discussed in the language of efficiency, competitiveness, and market access. During COVID, it became something far more urgent. The world needed rapid vaccine development, antiviral research, diagnostic capacity, decentralised trial models, scalable manufacturing, and regulatory flexibility. Countries with the ability to mobilise quickly were suddenly viewed very differently.

China entered that moment with an increasingly modernised regulatory system, an expanding biotech financing ecosystem, and growing domestic clinical research capability. The reforms of 2015 to 2018 were no longer theoretical policy changes. They became operational advantages in a world that had just learned how quickly pharmaceutical systems may need to respond.

This is perhaps the more interesting point. China’s acceleration in clinical development was not caused by a single reform, nor by the pandemic alone. It was the result of timing.

Regulatory reform created the framework.

Capital market reform improved the funding environment.

ICH alignment increased international credibility.

COVID created the urgency.

The result was a far faster and more visible emergence of China as a clinical development powerhouse.

For global pharmaceutical companies, CROs, biotech investors, and clinical operations leaders, this matters. China is no longer only relevant as a recruitment geography, manufacturing base, or commercial market. It is increasingly relevant as a source of innovation, a partner in development, and a strategic variable in global R&D planning.

That does not mean the model is without complexity. Questions remain around data transparency, geopolitical risk, regulatory interpretation, cross-border collaboration, intellectual property, and the long-term sustainability of biotech valuations. But those complexities do not make China less important. They make it more important to understand properly.

The key lesson from today’s discussion is that clinical development ecosystems are built through infrastructure, regulation, capital, and urgency. China had already built much of the engine before the pandemic. COVID simply pressed the accelerator.

As the pharmaceutical industry continues to rethink global development strategy, China’s rise should not be viewed as a sudden disruption. It should be viewed as the result of deliberate preparation meeting a historic moment of global urgency.

For those involved in clinical development, procurement, CRO selection, and global trial strategy, that distinction matters.